Recent large-scale sequencing studies have identified a great number of genes whose disruptions 26 cause neurodevelopmental disorders (NDDs). However, cell-type-specific functions of NDD genes and 27 their contributions to NDD pathology are unclear. Here, we integrated NDD genetics with single-cell 28 RNA sequencing data to identify cell-type and temporal convergence of genes involved in different 29 NDDs. By assessing the co-expression enrichment pattern of various NDD gene sets, we identified mid-30 fetal cortical neural progenitor cell development-more specifically, ventricular radial glia-to-31 intermediate progenitor cell transition at gestational week 10-as a key convergent point in autism 32 spectrum disorder (ASD) and epilepsy. Integrated gene ontology-based analyses further revealed that 33 ASD genes function as upstream regulators to activate neural differentiation and inhibit cell cycle during 34 the transition, whereas epilepsy genes function as downstream effectors in the same processes, offering a 35 potential explanation for the high comorbidity rate of the two disorders. Together, our study provides a 36 framework for investigating the cell-type-specific pathophysiology of NDDs. 37 38 57 Krishnan et al. 2016; Shohat et al. 2017; Lin et al. 2015). For example, Parikshak et al. (2013) applied the 58 weighted gene co-expression network analysis to identify modules of co-expressed genes that are 59 enriched for ASD genes (Parikshak et al. 2013). Their top-down analyses suggest that at the circuit level, 60 ASD genes are enriched in superficial cortical layers and glutamatergic projection neurons during fetal 61 cortical development. Willsey et al. (2013) took a bottom-up approach by focusing on nine high-62
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39
Over the past decade, large-scale exome and genome sequencing studies have firmly established 40 that de novo protein-altering variants contribute significantly to NDDs, including ASD (Iossifov et pleiotropic functions of these disease-associated genes, it is challenging to directly pinpoint disease-48 specific pathophysiology. However, given the similarity of phenotypic symptoms within each NDD, it is 49 reasonable to hypothesize that disease-causing genes in a specific NDD functionally converge on 50 common brain developmental events. Moreover, NDDs share genetic etiology and comorbidities are 51 frequently found, suggesting that convergences of different NDDs may overlap with each other (Anttila et To identify high-confidence risk genes associated with each NDD, we first interrogated genes 91 with de novo protein-altering variants for the four NDDs in the denovo-db database (Turner et al. 2017) 92 and non-redundant data for epilepsy (Epi) from two studies (EuroEPINOMICS-RES Consortium et al. 93 2017; Heyne et al. 2018 ). Loss-of-function (nonsense, frameshift, and canonical splice site) mutations 94 generally lead to disruption of gene function, whereas missense mutations can cause hypomorphic, 95 hypermorphic, antimorphic, or neomorphic effects. Thus, for each NDD, we divided the associated genes 96 into two categories: genes with de novo loss-of-function (dnLoF) mutations and genes with de novo 97 missense (dnMis) mutations. To select the most relevant genes for each NDD, we only included genes 98 with at least two or three (depending on gene set sizes) de novo mutations of the same category in each 99 specific disorder (see Methods). In total, we defined eight high-confidence NDD gene sets: dnLoF-ASD, 100 dnLoF-Epi, dnLoF-ID, dnLoF-DD, dnMis-ASD, dnMis-Epi, dnMis-ID, and dnMis-DD (Supplementary 101   Table S1A ). There are some overlaps among different gene sets, which is expected given the high 102 comorbidity among these NDDs (Supplementary Fig. S1 ).
104
Different NDD gene sets display distinct co-expression enrichment across major cortical cell types 105 Previous co-expression analyses on NDDs used transcriptomic data from bulk brain tissue 106 (Parikshak et astrocytes, oligodendrocyte progenitor cells (OPCs), and microglia. Thus, we performed co-expression 116 analyses of the different NDD gene sets using the transcriptomic data from each of these cell types.
117
We reasoned that if mutations in different genes can cause similar symptoms in affected 118 individuals, these genes are more likely to functionally converge at some processes and stages in brain 119 development, potentially within a specific cell type. This functional convergence should be reflected by 120 an increase in the level of co-expression within a particular NDD gene set compared with the overall co-121 expression level of all the expressed genes (background genes) in that cell type. We first calculated the 122 pairwise Spearman's correlation coefficients between background genes in each cell type and defined the 123 top 0.5% pairs of genes with the highest correlation coefficients as significant co-expressed gene pairs.
124
We then calculated the fraction of significant co-expressed gene pairs out of all pairs of genes in the NDD 125 gene set and divided it by 0.5% to get a co-expression fold enrichment score of the NDD gene set (see 126 Methods). A high co-expression fold enrichment score of an NDD gene set indicates that the genes in the 127 NDD gene set are more significantly co-expressed than background genes. To verify the enrichment in 128 NDD gene sets is indeed specific and disease-relevant, we also included several control gene sets, Supplementary Table S1A ).
132
We calculated co-expression fold enrichment scores for the eight NDD gene sets and four control 133 gene sets across the six major cell types ( Fig. 1A; Supplementary Fig. S2 ). In general, NDD gene sets 134 show significantly higher co-expression enrichment than control gene sets ( Fig. 1A; Supplementary Fig. 
135
S2 and S3). Several interesting co-expression enrichment patterns can be found. First, the majority of 136 NDD gene sets show high co-expression enrichment in NPCs, suggesting a convergent involvement of 137 NPCs in different NDDs (Fig. 1A) . Moreover, dnLoF-ASD and dnMis-Epi genes stand out as having the 138 highest co-expression enrichment scores in particular cell types ( Fig. 1A; Supplementary Fig. S4 ).
139
Specifically, dnLoF-ASD genes have the highest co-expression in NPCs (18.8-fold enrichment), 140 suggesting a significant contribution of NPCs to ASD pathophysiology ( Fig. 1A) . Interestingly, dnMis-141 ASD genes show low co-expression enrichment in the six major cell types ( Fig. 1A) . This is consistent 142 with the previous estimation that ~43% of dnLoF mutations contribute to ASD diagnosis but only ~13% 143 of dnMis mutations do so (Iossifov et al. 2014) . Instead, dnMis-Epi genes are highly co-expressed in 144 NPCs, excitatory neurons, and, more prominently, interneurons (Fig. 1A) . This is in line with previous 
151
To determine whether the observed co-expression enrichment reflects true biological signal or is 152 confounded by other factors (Crow et al. 2016; McCall et al. 2016; Skinnider et al. 2019 ), we 153 systematically tested the possible confounders. We found that the co-expression enrichment is robust to 154 changes in the co-expression threshold ( Supplementary Fig. S5 and S6) and correlation-based measures 155 of association ( Supplementary Fig. S7 ). The co-expression enrichment also remains similar after 156 controlling for gene set size difference ( Supplementary Fig. S8 ), gene expression level dependence 157 ( Supplementary Fig. S9 ), and severity of missense mutations ( Supplementary Fig. S10 ). Because cell 158 numbers vary across the six major cell types ( Fig. 1A ; Supplementary Table S1B ), we downsampled the 159 same number of cells for each major cell type to make the co-expression enrichment scores comparable.
160
We found that reducing cell numbers generally decreases the co-expression enrichment scores ( Fig. 1B,C; 161 Supplementary Fig. S11) , consistent with the previous finding that larger cell numbers facilitate the 162 reconstruction of more robust and coherent networks (Skinnider et al. 2019 ). However, even after 163 downsampling, dnLoF-ASD genes still have the highest co-expression in NPCs (Fig. 1B) , and dnMis-Epi 164 genes are still highly co-expressed in NPCs and interneurons (Fig. 1C) . Although we used percentile-165 based cutoff for co-expression enrichment analysis to mitigate the effect of global co-expression 166 differences across cell types, the findings are consistent with results from absolute correlation analysis 167 ( Supplementary Fig. S12 and S13 ). An unexpected finding is that dnMis-Epi genes have the highest co-168 expression in microglia after downsampling (Fig. 1C) . Although microglia have been implicated in 169 epilepsy (Vezzani et al. 2011 (Vezzani et al. , 2013 , we focused on NPCs and interneurons for further analysis as they 170 have larger sample sizes thus more robust signals. and interneurons, we further performed co-expression enrichment analysis of these two gene sets at 182 different time points. To overcome the effect caused by sample size difference and increase the accuracy 183 of co-expression enrichment score estimation, we focused on cell stages with at least 50 cells and 184 downsampled the same number of cells for each cell stage to make results comparable ( Fig. 2A-C; 185 Supplementary Fig. S16 ). Apart from NPCs and interneurons where ASD and epilepsy genes show 186 enrichment, we also included excitatory neurons for comparison ( Fig. 2B) .
187
In NPCs, dnLoF-ASD genes are highly co-expressed at GW10 and, to a lesser extent, GW16 (Fig .   188 2A; Supplementary Fig. S16A ). GW10 and GW16 are two critical developmental stages for NPCs.
189
NPCs can be further divided into three categories: ventricular radial glia (vRG) cells, outer radial glia 
193
At GW10, vRG cells give rise to IPCs in the SVZ which further differentiate into deep-layer 194 neurons (Nowakowski et al. 2016 ). Interestingly, dnLoF-ASD genes show little to no co-expression 195 enrichment in vRG cells or IPCs alone at GW10 ( Fig. 2D; Supplementary Fig. S17A and S18A).
196
However, a high co-expression enrichment score was found when vRG cells and IPCs were combined 197 ( Fig. 2D; Supplementary Fig. S17A and S18A) . Supplementary Fig. S19 presents several examples of 198 dnLoF-ASD gene pairs that show high co-expression during the vRG-to-IPC transition at GW10. These 199 results indicate that gene expression variations within vRG cells or IPCs barely contribute to the co-200 expression of dnLoF-ASD genes in NPCs at GW10. Instead, gene expression variations due to cell-type 201 differences between vRG cells and IPCs largely explain the co-expression enrichment. Consistent with 202 this, we found that the majority of dnLoF-ASD genes concurrently increase their expression during the 203 transition from vRG cells to IPCs at GW10 ( Fig. 2G ; Supplementary Table S2 ). In addition to dnLoF-204 ASD genes with ≥ 3 dnLoF mutations, ASD genes with one or two dnLoF mutations and all the SFARI 205 curated gene sets except category six (Basu et al. 2009 ) also display increased expression during the vRG-206 to-IPC transition ( Supplementary Fig. S21 ). Together, these results highlight the functional convergence 207 of ASD genes in the transition from vRG cells to IPCs at GW10.
208
At GW16, vRG cells not only give rise to IPCs in the SVZ but also produce oRG cells that will Fig. 2E; Supplementary Fig. S17B 214 and S18B). However, the co-expression enrichment is not increased in the combination of oRG cells and 215 IPCs, suggesting that gene expression variations both within oRG cells/IPCs and during their transition 216 contribute to the co-expression of dnLoF-ASD genes in NPCs at GW16 ( Fig. 2E,F; Supplementary Fig. 
217
S17B and S18B,C). Consistently, we found that dnLoF-ASD genes do not show expression change 218 during the transition at GW16 from vRG cells to oRG cells, vRG cells to IPCs, and oRG cells to IPCs 219 ( Supplementary Fig. S22 ). Similar results were obtained when analyzing dnMis-Epi genes in NPCs ( Fig.   220 2A,D-G; Supplementary Fig. S16A , S17, S18, S20 and S22), whereas the co-expression enrichment 221 score of dnMis-Epi genes at GW16 is generally lower compared with the score of dnLoF-ASD genes at 222 GW16 ( Fig. 2A) . Figure 2H ,I show co-expression network comparison between individual cell types and 223 the cell-type transition at GW10 for dnLoF-ASD and dnMis-Epi genes using the original sample size.
224
In excitatory neurons, both dnLoF-ASD and dnMis-Epi genes show moderate to no co-expression 225 enrichment ( Fig. 2B ) despite their elevated absolute correlation at GW16 (Supplementary Fig. S16B ). In 226 interneurons, dnMis-Epi genes are highly co-expressed at later developmental stages, particularly GW23 227 ( Fig. 2C; Supplementary Fig. S16C ). This coincides with the axon development and cell maturation 228 processes of interneurons in the prefrontal cortex (Zhong et al. 2018 ).
230
Co-expression pattern of ASD and epilepsy genes during the differentiation from NPCs to 231 excitatory neurons
232
The above analyses focused on co-expression within a major cell type, which mainly captures cell 233 maturation and state changes. To understand whether dnLoF-ASD or dnMis-Epi genes co-function during 234 cell differentiation, we analyzed the co-expression pattern of these two gene sets during NPC terminal 235 differentiation ( Fig. 3A,B) . Due to the sample size limitation ( Supplementary Table S1B ), we focused 236 on the NPC-to-excitatory neuron differentiation at GW10 and GW16 whose time-matched cell stages 237 containing at least 50 samples in both NPCs and excitatory neurons. Excitatory neurons sampled from 238 GW10 and GW16 are mostly deep-layer neurons and upper-layer neurons, respectively (Supplementary 239 Fig. S23 ). We found that both dnLoF-ASD and dnMis-Epi genes display lower co-expression enrichment 240 in either excitatory neurons or the combination of NPCs and excitatory neurons than in NPCs ( Fig. 3A,B; 241 Supplementary Fig. S24 ). Also, no co-expression increase was observed during the differentiation from 242 NPC subtypes to excitatory neurons ( Supplementary Fig. S25A,B and S26A-C). However, both dnLoF-243 ASD and dnMis-Epi genes tend to increase their expression during the NPC-to-excitatory neuron 244 differentiation, especially at GW16 ( Fig. 3C,D; Supplementary Fig. S25C ,D and S26D-F; Supplementary Table S3 ). These results suggest that at the individual gene level, ASD and epilepsy 246 genes generally become more abundant/important, yet their functions become more diverse and less 247 convergent in differentiated excitatory neurons than in NPCs.
249
Biological pathways associated with ASD and epilepsy genes during the NPC transition at GW10
250
The above analyses highlight that both dnLoF-ASD and dnMis-Epi genes converge in the vRG-251 to-IPC transition at GW10. To systematically pinpoint the function of these genes during this transition, 252 we developed a gene ontology (GO) functional analysis method called GO correlation analysis (see 253 Methods). GO correlation analysis was used to determine the correlation between a given gene set and 254 any GO term in a context-dependent manner. Using this method, we calculated Spearman's correlation 255 for all the GO biological process terms with ASD or epilepsy genes during the vRG-to-IPC transition at 256 GW10. We found that ASD genes are positively correlated with genes involved in neurogenesis and 257 neural differentiation ( Fig. 4A ; Supplementary Table S4A ) and are negatively correlated with genes 258 involved in cell cycle and cellular respiration ( Fig. 4C ; Supplementary Table S4C ). Like ASD genes, 259 genes in GO terms that show positive correlation also increase their expression during the transition ( Fig.   260 4A; Supplementary Table S4A ). Instead, genes in GO terms that show negative correlations, especially 261 those involved in the cell cycle, tend to decrease their expression during the transition ( Fig. 4C; 262 Supplementary Table S4C ). These observations are consistent with the fact that IPCs exhibit increased 263 neuronal commitment and decreased proliferation capacity compared with vRG cells (Noctor et al. 2004 ).
264
Similar results were obtained when dnMis-Epi genes were analyzed ( Fig. 4B,D ; Supplementary Table   265 S4B,D). These results suggest that both dnLoF-ASD and dnMis-Epi genes are involved in neuron 266 differentiation and cell cycle pathways during the transition.
268
Upstream versus downstream involvement of ASD and epilepsy genes during the NPC transition at 269 GW10 270 It seems that both dnLoF-ASD and dnMis-Epi genes are involved in the same biological 271 pathways during the NPC transition at GW10. However, the manifestations of these two disorders are 272 dissimilar, indicating that the underlying molecular and cellular mechanisms might be different. To 273 determine the difference in ASD versus epilepsy gene functions in NPCs, we examined the composition 274 of each gene set. We found that ASD genes are enriched in GO terms like chromatin modification and 275 organization, but not in the GO terms like neurogenesis and neural differentiation, which are positively 276 correlated with ASD genes ( Fig. 5A ; Supplementary Table S5A) 
294
The top 300 downregulated and top 300 upregulated genes in Chd8 haploinsufficiency versus wild-type 295 mice at each developmental stage were defined as CHD8-activated and -repressed genes, respectively (see 296 Methods and Supplementary Table S6A ). Interestingly, only CHD8-activated genes at E14.5 are both 297 preferentially bound by CHD8 (Gompers et al. 2017) and enriched for ASD genes (Supplementary Fig.   298 S27), suggesting that they are more likely genuine CHD8 target genes that involve in ASD pathology.
299
Thus, we deemed CHD8-activated and -repressed genes at E14.5 as CHD8 target genes in ASD.
300
We first analyzed the expression pattern of these CHD8 target genes in human GW10 NPCs. As 301 shown in Fig. 2H , CHD8 doubles its expression during the vRG-to-IPC transition at GW10 302 ( Supplementary Table S2 ). As expected, we observed that CHD8-activated target genes also exhibit 303 significant expression increase and CHD8-repressed target genes show significant expression decrease 304 compared with the background genes during the transition ( Fig. 6A ; Supplementary Table S6B ).
305
Consistently, CHD8 is more positively correlated with CHD8-activated target genes and more negatively 306 correlated with CHD8-repressed target genes than the background genes ( Fig. 6B ; Supplementary Table   307 S6C). Moreover, CHD8-activated target genes are enriched with GO terms related to neurogenesis and 308 neuron development ( Fig. 6C; Supplementary Table S6D ), whereas CHD8-repressed target genes are 309 enriched with GO terms related to cell cycle ( Fig. 6D; Supplementary Table S6E ). Together, these mechanisms. If this assumption is correct, one would expect that low-confidence NDD genes would also 328 converge to the core pathways. To test this possibility, we calculated Spearman's correlation with dnLoF-329 ASD genes in NPCs for dnLoF-ASD genes (with ≥ 3 dnLoF mutations) and ASD genes with fewer dnLoF 330 mutations. As expected, we found that ASD genes harboring two or one dnLoF mutations have a 331 significantly higher correlation with dnLoF-ASD genes than genes harboring no dnLoF mutations, 332 independently validating that the co-expression enrichment of dnLoF-ASD genes in NPCs captures the 333 true ASD pathology ( Fig. 7A; Supplementary Table S7A ). Similar results were obtained for dnMis-Epi 334 genes in interneurons ( Fig. 7B; Supplementary Table S7B ).
335
In addition, we found that the Spearman's correlations with dnLoF-ASD genes in NPCs for 336 dnLoF-ASD genes are significantly higher than those for ASD genes with fewer mutations, and the 337 Spearman's correlations with dnMis-Epi genes in interneurons for dnMis-Epi genes are significantly 338 higher than those for epilepsy genes with fewer mutations (Fig. 7A,B) . These results suggest that genes 339 with more mutations tend to be at the core position of the NDD gene co-expression network while genes 340 with fewer mutations tend to be in the peripheral region of the network. To test this hypothesis, we 341 constructed an NPC co-expression network of all the ASD genes with dnLoF mutations (Fig. 7C; 342 Supplementary Table S7C ) and an interneuron co-expression network of all the epilepsy genes with 343 dnMis mutations ( Fig. 7D; Supplementary Table S7D ). Consistent with our hypothesis, we found that 344 genes with more mutations tend to be at the core position of the network, as indicated by a significantly 345 higher co-expression degree than genes with fewer mutations (Fig. 7E,F; Supplementary Table S7E,F) .
346
Together, these findings validate that co-expression enrichment of NDD genes faithfully represents NDD 347 mechanisms and provide an explanation of why some NDD genes have more mutations identified than When analyzing the NDD gene sets, we found that for the same disorder, genes with different 365 types of mutations display distinct co-expression patterns. For instance, dnLoF-ASD genes have the 366 highest co-expression enrichment in NPCs among all the NDD gene sets, but dnMis-ASD genes barely 367 show any enrichment. Instead, dnLoF-Epi genes have the minimum co-expression enrichment in 368 interneurons, while dnMis-Epi genes have the highest enrichment in the same cell type. The exact causes 369 of these observations are not immediately clear. One potential explanation is that haploinsufficiency is the 370 major genetic mechanism for highly penetrant ASD genes. Conversely, gain-of-function or dominant-371 negative missense mutations dominate the mutational spectrum of highly penetrant genes in epilepsy.
372
Several lines of evidence support this hypothesis: 1) 43% of dnLoF mutations but only 13% of dnMis IPCs has a strong impact on the specificity and function of both the IPCs and the neuronal progeny to be 408 generated.
409
We found that both ASD and epilepsy genes have higher co-expression enrichment in NPCs than 410 in excitatory neurons. However, their expression levels are higher in excitatory neurons than in NPCs.
411
These findings indicate that at the individual gene level, ASD and epilepsy genes generally become more phenotype while all other "peripheral" genes contribute to the phenotype by affecting the functions of 441 these core genes. Due to evolutionary pressure, only a limited number of large-effect genetic variations in 442 core genes can be identified and a large fraction of the total genetic contribution to disease comes from 443 peripheral genes that do not play direct roles. A possible approach to identify core genes is to look for de 444 novo rare variants with large effect sizes. This model fits well with our observations that potential core 445 genes with multiple de novo rare variants in ASD and epilepsy are clustered at the more central position 446 in the co-expression network of relevant cell types while genes with fewer mutations tend to be in the 447 peripheral region. We noted that another kind of core gene which may function equally importantly 448 across cell types/stages/transitions should not be overlooked. Thus, our study not only provides a list of 449 core genes (such as ASD and epilepsy genes with high co-expression degree in Supplementary Table   450 S7E,F) and pathways but also identifies the most relevant cell types where these genes and pathways 
470
Although we used percentile-based cutoff for co-expression enrichment analysis to mitigate the effect of 471 global co-expression differences across cell types, the findings are consistent with results from the 472 absolute correlation analysis. The high co-expression enrichment score also reflects the absolute elevation 473 of co-expression level, especially for dnLoF-ASD genes in NPCs (Supplementary Fig. S12A ), dnMis-
474
Epi genes in interneurons (Supplementary Fig. S12B) , dnLoF-ASD and dnMis-Epi genes in NPCs at 475 GW10 and GW16 (Supplementary Fig. S16A) , and dnLoF-ASD and dnMis-Epi genes in the vRG-to-476 IPC transition at GW10 (Supplementary Fig. S18A) . Lastly, it is worth noting that the relatively small 477 sample size has limited our analysis to a few cell types and developmental stages. Besides, we are using 478 the scRNA-seq dataset from the mid-fetal stage of the developing human brain and our analyses primarily 479 focus on early mechanisms of NDDs, that is, transcriptional programs and cell-autonomous effects that 480 take place early in brain development. In the future, it could be fruitful to expand our analysis to more cell 481 types and developmental stages at both cell-autonomous and cell-cell interaction levels when larger 482 scRNA-seq datasets which also cover later developmental stages become available. 493 mutations in the gene. High-confidence dnLoF (dnMis) genes for ASD, epilepsy, ID, and DD were 494 defined as genes with at least three dnLoF (dnMis) mutations in each disorder. For high-confidence gene 495 sets with gene number less than 20 (dnLoF-Epi, dnLoF-ID, dnMis-Epi, and dnMis-ID), we used genes 496 with at least two de novo mutations. For comparison, we used genes with at least one dnLoF mutations in 497 unaffected ASD siblings in the denovo-db database as sibling control. We also used genes with at least 498 one LoF mutations in the ExAC database (Lek et al. 2016 ) with known neuropsychiatric cohorts removed 499 as general control. We further included Brain-GRF and synapse genes as controls for genes functioning in 500 the brain. The Brain-GRF gene set is a list of gene regulatory factors that are known to function in the 501 human brain from literature curation (Berto et al. 2016 ). The synapse gene set was obtained from the SynGO knowledge base (Koopmans et al. 2019 ). The SFARI ASD gene set was obtained from the SFARI 503 Gene database (Basu et al. 2009 ), and the SFARI ASD genes were grouped into syndromic genes 504 (category S) and genes with different evidence levels (categories 1-6; high confidence-low evidence). In 505 addition, we assessed whether pathogenicity metrics such as CADD score (Kircher et al. 2014 ) could 506 improve NDD gene sets with dnMis mutations. We focused on ASD and DD genes with a large number 507 of dnMis mutations available and obtained two high-confidence gene sets: ASD gene sets harboring at 508 least two dnMis mutations with CADD score>25, and DD gene sets harboring at least three dnMis 509 mutations with CADD score>25. 
548
Co-expression enrichment analysis
549
When constructing a co-expression network for the background genes in one cell type, the value 550 0.5% used for selection of correlation threshold was defined as co-expression network density for the 551 background genes. Similarly, the co-expression network density for a gene set was defined as the number 552 of significant co-expressed pairs divided by the number of all pairs between genes in the gene set. Then, 553 the co-expression fold enrichment score for the gene set was defined as the ratio of the co-expression 554 network density for the gene set to the co-expression network density for the background genes. The 555 statistical significance of the co-expression fold enrichment score of the gene set was assessed in two 556 ways. First, we compared the co-expression network density for the gene set against the co-expression 557 network density for the background genes by the one-sided Fisher's exact test with R function:
where A is the number of significant co-expressed pairs between genes in the gene set, B is the number of 559 all pairs between genes in the gene set, C is the number of significant co-expressed pairs between the 560 background genes, and D is the number of all pairs between the background genes. Second, we also 561 assessed the statistical significance of the co-expression fold enrichment score of the gene set by 562 comparing whether the gene set has a higher co-expression fold enrichment score than the other NDD 
582
Co-expression enrichment analysis by controlling for different factors
583
In addition to using the threshold of top 0.5% to construct co-expression networks and calculate 584 co-expression fold enrichment score for NDD gene sets in six major cell types, we used different 585 thresholds of top 0.25% and top 1%. We also varied the thresholds between top 0.1% and top 5% to 586 construct co-expression networks and calculate co-expression fold enrichment score for dnLoF-ASD 587 genes in NPCs and dnMis-Epi genes in interneurons. In addition to using Spearman's correlation to 588 construct co-expression networks and calculate co-expression fold enrichment score at the threshold of 589 top 0.5% for dnLoF-ASD genes in NPCs and dnMis-Epi genes in interneurons, we used another 16 590 measures of association implemented in the 'dismay' R package (Skinnider et al. 2019 ). Moreover, we 591 assessed the effect of gene set size difference on the co-expression fold enrichment score of NDD and 592 control gene sets in six major cell types. For each major cell types, we first determined the smallest gene 593 set size of NDD and control gene sets with genes expressed in the cell type. We then downsampled the 594 same number of genes (the smallest gene set size) 1000 times for each gene set to calculate the co-595 expression fold enrichment score. We further evaluated the dependence of gene expression on the co-596 expression fold enrichment score of NDD gene sets in six major cell types. For each major cell type, 597 genes expressed in the cell type were divided into ten bins based on expression level with each bin 598 containing the equal number of genes. For each gene set in each cell type, the co-expression enrichment 599 score was computed using 1000 randomly chosen same-size gene sets with the same expression 600 distribution across bins in the cell type as the background gene set.
601
Correlation with dnLoF-ASD and dnMis-Epi genes
602
For the calculation of correlation with dnLoF-ASD genes in NPCs, we used genes expressed in 603 NPCs as background genes. For any non-dnLoF-ASD gene expressed in NPCs, the correlation with 604 dnLoF-ASD genes for the gene was defined as the average Spearman's correlation coefficients between 605 the gene and dnLoF-ASD genes. For any dnLoF-ASD gene expressed in NPCs, the correlation with 606 dnLoF-ASD genes for the gene was defined as the average Spearman's correlation coefficients between 607 the gene and the other dnLoF-ASD genes. Based on the correlation with dnLoF-ASD genes for any gene 608 expressed in NPCs, we then obtained the distribution of correlations with dnLoF-ASD genes for different 609 types of mutated ASD genes. The differences in correlations between different ASD gene sets were 610 estimated using the one-sided Wilcoxon rank sum test. A similar analysis was performed to compute the 611 correlation with dnLoF-ASD genes during the transition from vRG cells to IPCs at GW10 using genes 612 expressed in NPCs as background genes. A similar analysis was performed to compute the correlation 613 with dnMis-Epi genes in interneurons and the transition from vRG cells to IPCs at GW10 using genes 614 expressed in interneurons and NPCs as background genes, respectively.
615
GO enrichment analysis of dnLoF-ASD and dnMis-Epi genes
616
To perform GO enrichment analysis, the ontology and human annotation files were downloaded 617 from the GO database (http://www.geneontology.org). To compute the overlap between dnLoF-ASD 618 genes and GO biological process terms during the transition from vRG cells to IPCs at GW10, we used 619 genes expressed in NPCs as background genes. Genes that are annotated under the GO terms but not 620 expressed in NPCs were removed. Only GO terms with the remaining gene number between 10 and 1000 621 after filtering were used for GO enrichment analysis. The statistical significance P values of the overlap 622 between dnLoF-ASD genes and GO terms were computed using the one-sided Fisher's exact test and 623 corrected for multiple hypothesis testing using false discovery rate (FDR) control procedure (Benjamini 624 and Hochberg 1995). For GO enrichment analysis of dnMis-Epi genes, the same process above was 625 repeated.
626
GO correlation analysis of dnLoF-ASD and dnMis-Epi genes during the cell-type transition
627
Based on the correlation with dnLoF-ASD genes during the vRG-to-IPC transition at GW10 for 628 any gene expressed in NPCs, we then obtained the distribution of correlations with dnLoF-ASD genes 629 during the transition for genes annotated under a GO biological process term. Only GO terms with the 980 981 
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